Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination

Ching Fen Shen; Yi Chen Fu; Tzong Shiann Ho; Po Lin Chen; Nan Yao Lee; Bo Yang Tsai; Pei Jane Tsai; Wen Chien Ko; Ching Chuan Liu; Chao Min Cheng; Chi Chang Shieh

doi:10.1016/j.clim.2023.109342

Pre-existing humoral immunity and CD4⁺ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination

Ching Fen Shen, Yi Chen Fu, Tzong Shiann Ho, Po Lin Chen, Nan Yao Lee, Bo Yang Tsai, Pei Jane Tsai, Wen Chien Ko, Ching Chuan Liu, Chao Min Cheng, Chi Chang Shieh

研究成果: Article › 同行評審

2 引文斯高帕斯（Scopus）

摘要

Background: Information regarding the heterologous prime-boost COVID vaccination has been fully elucidated. The study aimed to evaluate both humoral, cellular immunity and cross-reactivity against variants after heterologous vaccination. Methods: We recruited healthcare workers previously primed with Oxford/AstraZeneca ChAdOx1-S vaccines and boosted with Moderna mRNA-1273 vaccine boost to evaluate the immunological response. Assay used: anti-spike RBD antibody, surrogate virus neutralizing antibody and interferon-γ release assay. Results: All participants exhibited higher humoral and cellular immune response after the booster regardless of prior antibody level, but those with higher antibody level demonstrated stronger booster response, especially against omicron BA.1 and BA.2 variants. The pre-booster IFN-γ release by CD4⁺ T cells correlates with post-booster neutralizing antibody against BA.1 and BA.2 variant after adjustment with age and gender. Conclusions: A heterologous mRNA boost is highly immunogenic. The pre-existing neutralizing antibody level and CD4⁺ T cells response correlates with post-booster neutralization reactivity against the Omicron variant.

原文	English
文章編號	109342
期刊	Clinical Immunology
卷	251
DOIs	https://doi.org/10.1016/j.clim.2023.109342
出版狀態	Published - 2023 6月

All Science Journal Classification (ASJC) codes

免疫學和過敏
免疫學

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.1016/j.clim.2023.109342

其它文件與鏈接

引用此

Shen, C. F., Fu, Y. C., Ho, T. S., Chen, P. L., Lee, N. Y., Tsai, B. Y., Tsai, P. J., Ko, W. C., Liu, C. C., Cheng, C. M., & Shieh, C. C. (2023). Pre-existing humoral immunity and CD4⁺ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination. Clinical Immunology, 251, 文章 109342. https://doi.org/10.1016/j.clim.2023.109342

@article{3ad6ab3a908d4e44a4c379367e6f9635,

title = "Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination",

abstract = "Background: Information regarding the heterologous prime-boost COVID vaccination has been fully elucidated. The study aimed to evaluate both humoral, cellular immunity and cross-reactivity against variants after heterologous vaccination. Methods: We recruited healthcare workers previously primed with Oxford/AstraZeneca ChAdOx1-S vaccines and boosted with Moderna mRNA-1273 vaccine boost to evaluate the immunological response. Assay used: anti-spike RBD antibody, surrogate virus neutralizing antibody and interferon-γ release assay. Results: All participants exhibited higher humoral and cellular immune response after the booster regardless of prior antibody level, but those with higher antibody level demonstrated stronger booster response, especially against omicron BA.1 and BA.2 variants. The pre-booster IFN-γ release by CD4+ T cells correlates with post-booster neutralizing antibody against BA.1 and BA.2 variant after adjustment with age and gender. Conclusions: A heterologous mRNA boost is highly immunogenic. The pre-existing neutralizing antibody level and CD4+ T cells response correlates with post-booster neutralization reactivity against the Omicron variant.",

author = "Shen, {Ching Fen} and Fu, {Yi Chen} and Ho, {Tzong Shiann} and Chen, {Po Lin} and Lee, {Nan Yao} and Tsai, {Bo Yang} and Tsai, {Pei Jane} and Ko, {Wen Chien} and Liu, {Ching Chuan} and Cheng, {Chao Min} and Shieh, {Chi Chang}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = jun,

doi = "10.1016/j.clim.2023.109342",

language = "English",

volume = "251",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination

AU - Shen, Ching Fen

AU - Fu, Yi Chen

AU - Ho, Tzong Shiann

AU - Chen, Po Lin

AU - Lee, Nan Yao

AU - Tsai, Bo Yang

AU - Tsai, Pei Jane

AU - Ko, Wen Chien

AU - Liu, Ching Chuan

AU - Cheng, Chao Min

AU - Shieh, Chi Chang

PY - 2023/6

Y1 - 2023/6

N2 - Background: Information regarding the heterologous prime-boost COVID vaccination has been fully elucidated. The study aimed to evaluate both humoral, cellular immunity and cross-reactivity against variants after heterologous vaccination. Methods: We recruited healthcare workers previously primed with Oxford/AstraZeneca ChAdOx1-S vaccines and boosted with Moderna mRNA-1273 vaccine boost to evaluate the immunological response. Assay used: anti-spike RBD antibody, surrogate virus neutralizing antibody and interferon-γ release assay. Results: All participants exhibited higher humoral and cellular immune response after the booster regardless of prior antibody level, but those with higher antibody level demonstrated stronger booster response, especially against omicron BA.1 and BA.2 variants. The pre-booster IFN-γ release by CD4+ T cells correlates with post-booster neutralizing antibody against BA.1 and BA.2 variant after adjustment with age and gender. Conclusions: A heterologous mRNA boost is highly immunogenic. The pre-existing neutralizing antibody level and CD4+ T cells response correlates with post-booster neutralization reactivity against the Omicron variant.

AB - Background: Information regarding the heterologous prime-boost COVID vaccination has been fully elucidated. The study aimed to evaluate both humoral, cellular immunity and cross-reactivity against variants after heterologous vaccination. Methods: We recruited healthcare workers previously primed with Oxford/AstraZeneca ChAdOx1-S vaccines and boosted with Moderna mRNA-1273 vaccine boost to evaluate the immunological response. Assay used: anti-spike RBD antibody, surrogate virus neutralizing antibody and interferon-γ release assay. Results: All participants exhibited higher humoral and cellular immune response after the booster regardless of prior antibody level, but those with higher antibody level demonstrated stronger booster response, especially against omicron BA.1 and BA.2 variants. The pre-booster IFN-γ release by CD4+ T cells correlates with post-booster neutralizing antibody against BA.1 and BA.2 variant after adjustment with age and gender. Conclusions: A heterologous mRNA boost is highly immunogenic. The pre-existing neutralizing antibody level and CD4+ T cells response correlates with post-booster neutralization reactivity against the Omicron variant.

UR - http://www.scopus.com/inward/record.url?scp=85154541138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85154541138&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2023.109342

DO - 10.1016/j.clim.2023.109342

M3 - Article

C2 - 37100338

AN - SCOPUS:85154541138

SN - 1521-6616

VL - 251

JO - Clinical Immunology

JF - Clinical Immunology

M1 - 109342

ER -